Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

58 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Farrar JT, et al. Among authors: werth jl. Pain. 2001 Nov;94(2):149-58. doi: 10.1016/s0304-3959(01)00349-9. Pain. 2001. PMID: 11690728 Clinical Trial.
Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study.
Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein MB, Lydiard RB, Futterer R, Robinson P, Slomkowski M, DuBoff E, Phelps M, Janney CA, Werth JL. Pande AC, et al. Among authors: werth jl. J Clin Psychopharmacol. 2004 Apr;24(2):141-9. doi: 10.1097/01.jcp.0000117423.05703.e7. J Clin Psychopharmacol. 2004. PMID: 15206660 Clinical Trial.
A method for determining the magnitude of change across different cognitive functions in clinical trials: the effects of acute administration of two different doses alprazolam.
Snyder PJ, Werth J, Giordani B, Caveney AF, Feltner D, Maruff P. Snyder PJ, et al. Among authors: werth j. Hum Psychopharmacol. 2005 Jun;20(4):263-73. doi: 10.1002/hup.692. Hum Psychopharmacol. 2005. PMID: 15912482 Clinical Trial.
A statistical approach for classifying change in cognitive function in individuals following pharmacologic challenge: an example with alprazolam.
Maruff P, Werth J, Giordani B, Caveney AF, Feltner D, Snyder PJ. Maruff P, et al. Among authors: werth j. Psychopharmacology (Berl). 2006 May;186(1):7-17. doi: 10.1007/s00213-006-0331-5. Epub 2006 Mar 28. Psychopharmacology (Berl). 2006. PMID: 16572266 Clinical Trial.
Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group.
Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G. Pande AC, et al. Among authors: werth jl. Bipolar Disord. 2000 Sep;2(3 Pt 2):249-55. doi: 10.1034/j.1399-5618.2000.20305.x. Bipolar Disord. 2000. PMID: 11249802 Clinical Trial.
How modeling and simulation have enhanced decision making in new drug development.
Miller R, Ewy W, Corrigan BW, Ouellet D, Hermann D, Kowalski KG, Lockwood P, Koup JR, Donevan S, El-Kattan A, Li CS, Werth JL, Feltner DE, Lalonde RL. Miller R, et al. Among authors: werth jl. J Pharmacokinet Pharmacodyn. 2005 Apr;32(2):185-97. doi: 10.1007/s10928-005-0074-7. Epub 2005 Nov 7. J Pharmacokinet Pharmacodyn. 2005. PMID: 16283534 Review.
A Randomized, Double-Blind, Phase 2 Study of the Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity, Safety and Amyloid Imaging in Patients with Mild to Moderate Alzheimer's Disease.
Ketter N, Liu E, Di J, Honig LS, Lu M, Novak G, Werth J, LePrince Leterme G, Shadman A, Brashear HR. Ketter N, et al. Among authors: werth j. J Prev Alzheimers Dis. 2016;3(4):192-201. doi: 10.14283/jpad.2016.118. J Prev Alzheimers Dis. 2016. PMID: 29199321
Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit.
Corrigan B, Feltner DE, Ouellet D, Werth JL, Moton AE, Gibson G. Corrigan B, et al. Among authors: werth jl. Br J Clin Pharmacol. 2009 Aug;68(2):174-80. doi: 10.1111/j.1365-2125.2009.03444.x. Br J Clin Pharmacol. 2009. PMID: 19694735 Free PMC article. Clinical Trial.
The use of a clinical utility index to compare insomnia compounds: a quantitative basis for benefit-risk assessment.
Ouellet D, Werth J, Parekh N, Feltner D, McCarthy B, Lalonde RL. Ouellet D, et al. Among authors: werth j. Clin Pharmacol Ther. 2009 Mar;85(3):277-82. doi: 10.1038/clpt.2008.235. Epub 2008 Dec 10. Clin Pharmacol Ther. 2009. PMID: 19078947 Clinical Trial.
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease.
Brody M, Liu E, Di J, Lu M, Margolin RA, Werth JL, Booth K, Shadman A, Brashear HR, Novak G. Brody M, et al. Among authors: werth jl. J Alzheimers Dis. 2016 Oct 18;54(4):1509-1519. doi: 10.3233/JAD-160369. J Alzheimers Dis. 2016. PMID: 27589523 Clinical Trial.
58 results
Jump to page
Feedback